



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/620,532	07/16/2003	Peggy J. Farnham	960296.98750	3318
26734	7590	09/23/2005	EXAMINER	
QUARLES & BRADY LLP FIRSTAR PLAZA, ONE SOUTH PINCKNEY STREET P.O. BOX 2113 SUITE 600 MADISON, WI 53701-2113			AEDER, SEAN E	
		ART UNIT	PAPER NUMBER	
		1642		

DATE MAILED: 09/23/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/620,532	FARNHAM ET AL.
	Examiner	Art Unit
	Sean E. Aeder, Ph.D.	1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM
THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-39 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-39 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date: _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date: _____ | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-10 and 34-39 (in part), specifically drawn to an isolated nucleic acid and a kit comprising a polynucleotide probe, classified in class 536, subclass 23.1.

(Upon election of group I, Applicant must select SEQ ID NO:2 and SEQ ID NO:1 or SEQ ID NO:3 and SEQ ID NO:4 as each pair represents a separate invention and not a species.)

- II. Claims 11-16, drawn to an isolated polypeptide, classified in class 530, subclass 350.

(Upon election of group II, Applicant must select either SEQ ID NO:2 or SEQ ID NO:4 as each represents a separate invention and not a species.)

- III. Claims 17, 18, and 34-39 (in part), drawn to an antibody, classified in class 424, subclass 130.1.

(Upon election of group III, Applicant must select either SEQ ID NO:2 or SEQ ID NO:4 as each represents a separate invention and not a species.)

IV. Claims 19-21, specifically drawn to a method for identifying an agent that can modulate the expression of a polynucleotide wherein the expression is measured at the mRNA level, classified in class 435, subclass 6.

(Upon election of group IV, Applicant must select either SEQ ID NO:2 or SEQ ID NO:4 as each represents a separate invention and not a species.)

V. Claims 19, 20, and 22, specifically drawn to a method for identifying an agent that can modulate the expression of a polynucleotide wherein the expression is measured at the protein level, classified in class 435, subclass 7.1.

(Upon election of group V, Applicant must select either SEQ ID NO:2 or SEQ ID NO:4 as each represents a separate invention and not a species.)

VI. Claims 23-26, specifically drawn to a method for diagnosing a cancer or preneoplastic development comprising measuring the expression of a polynucleotide, classified in class 435, subclass 6.

(Upon election of group VI, Applicant must select either SEQ ID NO:2 or SEQ ID NO:4 as each represents a separate invention and not a species.)

VII. Claims 23, 24, 25, and 27, specifically drawn to a method for diagnosing a cancer or preneoplastic development comprising measuring the expression of a protein, classified in class 435, subclass 7.1.

(Upon election of group VII, Applicant must select either SEQ ID NO:2 or SEQ ID NO:4 as each represents a separate invention and not a species.)

VIII. Claims 28-30, drawn to a method for identifying a candidate for further screening comprising determining the level of a polypeptide, classified in class 435, subclass 7.1.

(Upon election of group VIII, Applicant must select either SEQ ID NO:2 or SEQ ID NO:4 as each represents a separate invention and not a species.)

IX. Claims 31-33, drawn to a method for identifying a candidate for further screening comprising determining the level of an antibody, classified in class 435, subclass 7.1.

(Upon election of group IX, Applicant must select either SEQ ID NO:2 or SEQ ID NO:4 as each represents a separate invention and not a species.)

The inventions are distinct, each from the other because of the following reasons:

The inventions of groups I-III represent separate and distinct products. Group I is drawn to a polynucleotide, group II is drawn to a protein, and group III is drawn to an antibody. These products are made by materially different methods, and are used in materially different methods which have different modes of operation, different functions and different effects.

The DNA of group I is related to the protein of group II by virtue of the fact that the DNA codes for the protein. The DNA molecule has utility for the recombinant production of the protein in a host cell. Although the DNA and the protein are related, since the DNA encodes the specifically claimed protein, they are distinct inventions because the protein product can be made by other and materially distinct processes, such as purification from the natural source. Further, DNA can be used for processes other than the production of protein, such as nucleic acid hybridization assays.

Furthermore, searching the inventions of groups I and II together would impose a serious search burden. In the instant case, the search of the polypeptides and polynucleotides are not coextensive. The inventions of groups I and II have a separate status in the art as shown by their different classifications. In cases such as this one where descriptive sequence information is provided, the sequences are searched in appropriate database. There is search burden also in the non-patent literature. Prior to the concomitant isolation and expression of the sequences of interest there may be

Art Unit: 1642

journal articles devoted solely to polypeptides which would not have described the polynucleotide. Similarly, there may have been "classical" genetics papers which had no knowledge of the polypeptide but spoke to the gene. Searching, therefore is not coextensive. A search of the nucleic acid molecules of group I would require an oligonucleotide search, which is not likely to result in relevant art with respect to the polypeptide of group II. As such, it would be burdensome to search the inventions of groups I and II.

The polypeptide of group II and the antibody of group III are patentably distinct for the following reasons:

While the inventions of both group II and group III are polypeptides, in this instance the polypeptide of group II represents a purified CRG-L2 polypeptide, whereas the polypeptide of group III encompasses antibodies including IgG which comprises 2 heavy and 2 light chains containing constant and variable regions, and including framework regions which act as a scaffold for the 6 complementarily determining regions (CDR) that function to bind an epitope. Thus the polypeptide of group II and the antibody of group III are structurally distinct molecules; any relationship between a polypeptide of group II and an antibody of group III is dependent upon the correlation between the scope of the polypeptide that the antibody binds and the scope of the antibodies that would be generated upon immunization with the polypeptide.

In this case, the polypeptide of group II contains potentially hundreds of regions to which an antibody may bind, whereas the antibody of group III is defined in terms of its binding specificity to a small structure. Furthermore, searching the inventions of group II and group III would impose a serious search burden. The inventions have separate status in the art as shown by their different classifications. A polypeptide and an antibody which binds to the polypeptide require different searches. An amino acid sequence search of the full-length protein is necessary for a determination of novelty and unobviousness of the protein. However, such a search is not required to identify the antibody of group III. Furthermore, antibody which binds to an epitope of a polypeptide of group II may be known even if a polypeptide of group II is novel. In addition, the technical literature search for the polypeptide of group II and the antibody of group III are not coextensive, e.g., antibodies may be characterized in the technical literature prior to discovery of or sequence of their binding target.

The polynucleotide of group I and the antibody of group III are patentably distinct for the following reasons:

The antibody of group III includes, for example, IgG molecules which comprise 2 heavy and 2 light chains containing constant and variable regions, and including framework regions which act as a scaffold for the 6 complementarily determining regions (CDRs). Polypeptides, such as the antibody of group III which are composed of amino acids, and polynucleotides, which are composed of nucleic acids, are structurally

distinct molecules; any relationship between a polynucleotide and polypeptide is dependent upon the information provided by nucleic acid sequence open reading frame as it corresponds to the primary amino acid sequence of the encoded polypeptide. In the present claims, a polynucleotide of group I will not encode an antibody of group III, and the antibody of group III cannot be encoded by a polynucleotide of group I. Therefore, the antibody and polynucleotide are patentably distinct.

The antibody and polynucleotide inventions have a separate status in the art as shown by their different classifications. Furthermore, searching the inventions of group I and group III would impose a serious search burden since a search of the polynucleotides of group I would not be used to determine the patentability of any antibody of group III, and vice-versa.

The inventions of groups I-IX are materially distinct methods. Group IV is drawn to a method for identifying an agent that can modulate the expression of a polynucleotide wherein the expression is measured at the mRNA level, group V is drawn to a method for identifying an agent that can modulate the expression of a polynucleotide wherein the expression is measured at the protein level, group VI is drawn to a method for diagnosing cancer or preneoplastic development comprising measuring the expression of a polynucleotide, group VII is drawn to a method for diagnosing cancer or preneoplastic development comprising measuring the expression of a protein, group VIII is drawn to a method for identifying a candidate for further

screening comprising determining the level of a polypeptide, and group IX is drawn to a method for identifying a candidate for further screening comprising determining the level of an antibody. These methods differ at least in objectives, method steps, reagents and/or dosages and/or schedules used, response variables, and criteria for success.

Inventions I and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polynucleotide can be used in the materially different process of affinity chromatography.

Inventions I and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polynucleotide can be used in the materially different process of gene therapy.

Inventions III and VII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the

Art Unit: 1642

process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the antibody can be used in the materially different process of affinity chromatography.

Inventions III and VIII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the antibody can be used in the materially different process of affinity chromatography.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Species

Claim 24 is generic to a plurality of disclosed patentably distinct species comprising the following: tissues. The products of the above species represent separate and distinct cell types with different morphologies and functions such that one species could not be interchanged with the other. As such, each species would require different searches and the consideration of different patentability issues. Applicant is

required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Note:

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain

dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sean E. Aeder, Ph.D. whose telephone number is 571-272-8787. The examiner can normally be reached on M-F: 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SEA



GARY B. NICKOL, PH.D.
PRIMARY EXAMINER